- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00262067
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Geelong, Australien, 3220
-
Malvern, Australien, 3144
-
Melbourne, Australien, 3002
-
Perth, Australien, 6008
-
Southport, Australien, 4215
-
Wahroonga, Australien, 2076
-
Waratah, Australien, 2298
-
Wollongong, Australien, 2500
-
-
-
-
-
Porto Alegre, Brasilien, 91350-200
-
Rio de Janeiro, Brasilien, 22260-020
-
Salvador, Brasilien, 40170-110
-
Santo Andre, Brasilien, 09060-870
-
Sao Paulo, Brasilien, 03102-002
-
-
-
-
-
Marseille, Frankreich, 13273
-
Paris, Frankreich, 75248
-
Reims, Frankreich, 51100
-
Saint Herblain, Frankreich, 44805
-
Strasbourg, Frankreich, 67010
-
-
-
-
-
Athens, Griechenland, 11521
-
Hania, Griechenland, 73300
-
Heraklion, Griechenland, 71110
-
Patras, Griechenland, 26500
-
Thessaloniki, Griechenland, 57001
-
-
-
-
-
Guatemala City, Guatemala, 01015
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
-
-
Quebec
-
Montreal, Quebec, Kanada, H2W 1S6
-
Montreal, Quebec, Kanada, H2L 4M1
-
-
-
-
-
Kyunggi-do, Korea, Republik von, 411-769
-
Seoul, Korea, Republik von, 110-744
-
Seoul, Korea, Republik von, 120-752
-
-
-
-
-
Acapulco, Mexiko, 39670
-
Aguascalientes, Mexiko, 20230
-
Merida, Mexiko, 97500
-
Monterrey, Mexiko, 64020
-
Monterrey, Mexiko, 64380
-
-
-
-
-
Amstelveen, Niederlande, 1186 AH
-
Apeldoorn, Niederlande, 7334 DZ
-
Delft, Niederlande, 2600 GA
-
-
-
-
-
Oslo, Norwegen, 0407
-
Oslo, Norwegen, 0310
-
-
-
-
-
Panama City, Panama
-
-
-
-
-
Callao, Peru
-
-
-
-
-
Quezon City, Philippinen, 1114
-
-
-
-
-
Chelyabinsk, Russische Föderation, 454 087
-
Ivanovo, Russische Föderation, 153040
-
Kazan, Russische Föderation, 420029
-
Kazan, Russische Föderation, 420111
-
Moscow, Russische Föderation, 115478
-
Moscow, Russische Föderation, 129128
-
Moscow, Russische Föderation, 117837
-
Novosibirsk, Russische Föderation, 630047
-
Obninsk, Russische Föderation, 249036
-
Ryazan, Russische Föderation, 390011
-
Samara, Russische Föderation, 443066
-
St Petersburg, Russische Föderation, 197758
-
UFA, Russische Föderation, 450054
-
-
-
-
-
Gaevle, Schweden, 80187
-
Uppsala, Schweden, 751 85
-
Örebro, Schweden, 701 85
-
-
-
-
-
Singapore, Singapur, 119228
-
Singapore, Singapur, 169610
-
-
-
-
-
Córdoba, Spanien, 14004
-
Elche, Spanien, 03203
-
Girona, Spanien, 17007
-
La Coruna, Spanien, 15006
-
La Laguna, Spanien, 38320
-
Madrid, Spanien, 28034
-
Santander, Spanien, 39008
-
Sevilla, Spanien, 41013
-
Valencia, Spanien, 46010
-
Zaragoza, Spanien, 50009
-
-
-
-
-
Tainan, Taiwan, 704
-
Taoyuan, Taiwan, 333
-
-
-
-
-
Cherkassy, Ukraine, 18009
-
Dnipropetrovsk, Ukraine, 49102
-
Kiev, Ukraine, 03115
-
Lvov, Ukraine, 79031
-
Odessa, Ukraine, 65055
-
Zaporozhye, Ukraine, 69104
-
-
-
-
-
Montevideo, Uruguay, 11200
-
-
-
-
California
-
Fullerton, California, Vereinigte Staaten, 92835
-
Santa Barbara, California, Vereinigte Staaten, 93105
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
-
Sioux City, Iowa, Vereinigte Staaten, 51101
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214-3728
-
-
-
-
-
Chelsmford, Vereinigtes Königreich, CM1 7ET
-
Cottingham, Vereinigtes Königreich, HU16 5JQ
-
Epping, Vereinigtes Königreich, CM16 6TN
-
Huddersfield, Vereinigtes Königreich, HD3 3EA
-
Nottingham, Vereinigtes Königreich, NG5 1PB
-
Sheffield, Vereinigtes Königreich, S1O 2SJ
-
Swansea, Vereinigtes Königreich, SA2 8QA
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease.
- Signed Informed Consent Form.
- Age ≥ 18 years.
- For women of childbearing potential, use of accepted and effective method of non-hormonal contraception.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Ability and capacity to comply with study and follow-up procedures.
- For anthracycline cohort only: Adequate left ventricular function at study entry, defined as a left ventricular ejection fraction (LVEF) ≥ 50% by either multigated acquisition (MUGA) scan scan or echocardiography (ECHO).
- For subjects who have received recent radiation therapy, recovery prior to baseline (Day 0) from any significant (Grade ≥ 3) acute toxicity.
Exclusion Criteria:
- Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive status.
- Prior chemotherapy for locally recurrent or metastatic disease.
- Prior hormonal therapy less than 1 week prior to Day 0.
- Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.
- For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant therapy for localized breast cancer.
- Investigational therapy within 28 days of Day 0.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
- Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to Day 0.
- Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
- Known brain or other central nervous system (CNS) metastases.
- Blood pressure of > 150/100 mmHg.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).
- History of myocardial infarction within 6 months prior to Day 0.
- History of stroke or transient ischemic attack within 6 months prior to Day 0.
- Clinically significant peripheral vascular disease.
- Evidence of bleeding diathesis or coagulopathy.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
- Serious non-healing wound, ulcer, or bone fracture.
- Pregnancy (positive serum pregnancy test) or lactation.
- Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; platelet count < 100,000/uL; total bilirubin > 1.5 mg/dL; alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal (ULN) (> 5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone involvement); alkaline phosphatase > 2x ULN (> 7x ULN in subjects with known bone involvement); serum creatinine > 2.0 mg/dL; partial thromboplastin time (PTT) and/or either international normalized ratio (INR) or prothrombin time (PT) > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); urine protein/creatinine ratio > 1.0 at screening for U.S. subjects, or urine dipstick for proteinuria >/= 1+ at screening followed by 24-hour urine collection demonstrating > 1 g protein/24 hr for ex-U.S. subjects.
- Uncontrolled serious medical or psychiatric illness.
- Active infection requiring intravenous (iv) antibiotics at Day 0.
- History of other malignancies within 5 years of Day 0 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix (subjects with a history of bilateral breast cancer will be eligible).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Bevacizumab + chemotherapy
Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
|
Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months.
The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study.
The initial dose was delivered over 90±10 minutes.
If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes.
If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
Andere Namen:
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle |
Placebo-Komparator: Placebo + chemotherapy
Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
|
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle
Placebo consisted of the vehicle for bevacizumab without the antibody.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions.
For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.
Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically.
All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST.
For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Overall Survival
Zeitfenster: Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
Overall survival was defined as the time from randomization until death from any cause.
|
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
1-year Survival
Zeitfenster: Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
1-year survival was defined as the percentage of patients who were alive 1 year after randomization. The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method. |
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Leonardo Faoro, MD, Genentech, Inc.
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AVF3694g
- BO20094 (Andere Kennung: Hoffmann-La Roche)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierter Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Bevacizumab
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Klarzelliges Zystadenokarzinom der Eierstöcke | Endometrioides Adenokarzinom der Eierstöcke | Seröses Zystadenokarzinom der Eierstöcke | Klarzelliges Adenokarzinom des Endometriums und andere BedingungenVereinigte Staaten
-
M.D. Anderson Cancer CenterRekrutierungHepatozelluläres Karzinom im Stadium IB AJCC v8 | Hepatozelluläres Karzinom Stadium II AJCC v8 | Resektables hepatozelluläres Karzinom | Hepatozelluläres Karzinom im Stadium I AJCC v8 | Hepatozelluläres Karzinom im Stadium IA AJCC v8Vereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenZervikales Adenokarzinom | Zervikales adenosquamöses Karzinom | Zervikales Plattenepithelkarzinom, nicht anders angegeben | Stadium IVA Gebärmutterhalskrebs AJCC v6 und v7 | Rezidivierendes Zervixkarzinom | Stadium IV Gebärmutterhalskrebs AJCC v6 und v7 | Stadium IVB Gebärmutterhalskrebs AJCC...Vereinigte Staaten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRekrutierungRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Rezidivierendes seröses Adenokarzinom des Endometriums | Klarzelliges Adenokarzinom der Eierstöcke | Rezidivierendes platinresistentes Ovarialkarzinom | Platinsensitives Ovarialkarzinom und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)NRG OncologyAbgeschlossenGlioblastom | Gliosarkom | Rezidivierendes Glioblastom | Oligodendrogliom | Riesenzell-Glioblastom | Wiederkehrende Neoplasie des GehirnsVereinigte Staaten, Kanada
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendStadium IV Hautmelanom AJCC v6 und v7 | Stadium IIIC Hautmelanom AJCC v7 | Nicht resezierbares MelanomVereinigte Staaten
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, nicht rekrutierendBösartiges solides Neoplasma | Endometrioides Adenokarzinom der Eierstöcke | Ovariales undifferenziertes Karzinom | Zervikales Adenokarzinom | Zervikales adenosquamöses Karzinom | Bösartige peritoneale Neubildung | Klarzelliges Adenokarzinom des Endometriums | Endometrium Endometrioides Adenokarzinom und andere BedingungenVereinigte Staaten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutierungRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Endometrioides Adenokarzinom der Eierstöcke | Klarzelliges Adenokarzinom der Eierstöcke | Klarzelliges Adenokarzinom des Eileiters | Endometrioides Adenokarzinom des Eileiters | Seröses... und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendMetastasierendes alveoläres Weichteilsarkom | Nicht resezierbares alveoläres WeichteilsarkomVereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendEndometrioides Adenokarzinom der Eierstöcke | Primäres peritoneales hochgradiges seröses Adenokarzinom | Endometrioides Adenokarzinom des Eileiters | Platinresistentes Eileiterkarzinom | Platinresistentes primäres Peritonealkarzinom | Ovariales hochgradiges seröses Adenokarzinom | Platinresistentes... und andere BedingungenVereinigte Staaten, Kanada